Chemoprevention with Somatuline© Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1)
暂无分享,去创建一个
V. Fendrich | D. Bartsch | B. Joos | E. Slater | C. Bollmann | J. Manoharan | M. Albers | Sylvia Roth | C. Lopez | Aninja Bayer | Carmen Bollmann
[1] A. Grossman,et al. Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1–Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression , 2016, Endocrinology.
[2] V. Fendrich,et al. Minimally Invasive Versus Open Pancreatic Surgery in Patients with Multiple Endocrine Neoplasia Type 1 , 2016, World Journal of Surgery.
[3] R. Iyer,et al. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors , 2016, Current Oncology Reports.
[4] P. Ruszniewski,et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study , 2016, Endocrine-related cancer.
[5] C. Schade-Brittinger,et al. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival , 2016, Neuroendocrinology.
[6] J. Strosberg,et al. The Expanding Role of Somatostatin Analogs in Gastroenteropancreatic and Lung Neuroendocrine Tumors , 2015, Drugs.
[7] D. Coppola,et al. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. , 2014, Endocrine-related cancer.
[8] B. Elmunzer,et al. Long-term Follow-up of Asymptomatic Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type I Syndrome , 2013, Journal of clinical gastroenterology.
[9] B. Skogseid,et al. Multiple microvascular alterations in pancreatic islets and neuroendocrine tumors of a Men1 mouse model. , 2013, The American journal of pathology.
[10] S. Libutti,et al. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model. , 2012, Surgery.
[11] J. Bilezikian,et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). , 2012, The Journal of clinical endocrinology and metabolism.
[12] M. Falconi,et al. ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors , 2011, Neuroendocrinology.
[13] R. Jensen,et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. , 2010, Pancreas.
[14] A. Tabarin,et al. Risk Factors and Causes of Death in MEN1 Disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) Cohort Study Among 758 Patients , 2010, World Journal of Surgery.
[15] B. Harding,et al. Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia , 2009, Endocrine-related cancer.
[16] M. Korbonits,et al. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. , 2008, Endocrine-related cancer.
[17] G. Feldmann,et al. Hedgehog signaling is required for effective regeneration of exocrine pancreas. , 2008, Gastroenterology.
[18] E. Baudin,et al. Prospective Endoscopic Ultrasonographic Evaluation of the Frequency of Nonfunctioning Pancreaticoduodenal Endocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1 , 2006, The American Journal of Gastroenterology.
[19] J. Chayvialle,et al. Epidemiology Data on 108 MEN 1 Patients From the GTE With Isolated Nonfunctioning Tumors of the Pancreas , 2006, Annals of surgery.
[20] J. Carney,et al. Familial Multiple Endocrine Neoplasia: The First 100 Years , 2005, The American journal of surgical pathology.
[21] A. Gozzini,et al. Multiple endocrine neoplasia type 1 , 2006, Orphanet journal of rare diseases.
[22] Zhao-Qi Wang,et al. Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. , 2003, Molecular endocrinology.
[23] M. Papotti,et al. Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors , 2002, Virchows Archiv.
[24] W. Simonds,et al. Multiple endocrine neoplasia type 1: new clinical and basic findings , 2001, Trends in Endocrinology & Metabolism.
[25] N. Vaysse,et al. Antiproliferative Effect of Somatostatin and Analogs , 2001, Chemotherapy.
[26] J. Mulvihill,et al. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. , 1998, Surgery.
[27] L. Liotta,et al. Multiple Endocrine Neoplasia Type 1: Clinical and Genetic Topics , 1998, Annals of Internal Medicine.
[28] Y Wang,et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. , 1997, Science.
[29] C. Edwards,et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1) , 1996, QJM : monthly journal of the Association of Physicians.